Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

[News]

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

More... (http://www.news-medical.net/news/20091203/Update-on-Celsions-ThermoDox-Phase-III-e2809cHEATe2809d-trial-for-HCC.aspx)